How Depo-Provera Affects Bone Density and Fracture Risk

Depo-Provera (depot medroxyprogesterone acetate, or DMPA) does reduce bone mineral density during use, with most of the loss concentrated in the first two years. The good news is that bone density recovers after you stop, and whether this temporary dip translates into actual broken bones later in life remains genuinely uncertain. The FDA added a black box warning about bone loss in 2004, which shaped how doctors prescribe the shot, but many professional organizations have pushed back on the idea that the warning should scare people away from an otherwise effective contraceptive.

How Much Bone Density Do You Lose

The numbers are consistent across multiple studies: during the first two years on Depo-Provera, you can expect to lose roughly 3 to 6 percent of bone density at the hip and spine. One study tracking first-time users found hip density dropped about 2.8 percent after one year and 5.8 percent after two years, with spine losses following a similar pattern. Control participants who were not on DMPA changed less than 1 percent over the same period.¹ A longer follow-up over four years showed cumulative losses of about 7.7 percent at the hip and 6.4 percent at the spine, but the rate of loss slowed dramatically after the two-year mark, dropping to less than 0.6 percent per year.²

That slowing matters. Your body appears to reach a new equilibrium after a couple of years on the shot. The bone loss does not just keep accelerating with each injection for as long as you use it. Researchers have suggested that because most of the decline happens early, staying on DMPA beyond two years may not substantially increase your risk of osteoporosis compared to stopping at two years.³ This is a point that often gets lost in the conversation. Many people hear “bone loss” and picture a progressive slide that gets worse the longer you stay on the drug, but the trajectory looks more like a steep initial dip followed by a plateau.

Why DMPA Affects Bone

DMPA works by suppressing ovulation, and in doing so it also suppresses estrogen production. Estrogen plays a central role in maintaining bone density by slowing the rate at which old bone is broken down. When estrogen drops, bone resorption (the removal of old bone tissue) outpaces bone formation, and the net effect is a loss of density. The mechanism is essentially the same one that drives bone loss in menopause, just triggered by a medication instead of aging. This is also why the loss partially levels off over time: the body adjusts its remodeling balance, and the rate of breakdown slows even while estrogen remains suppressed.

Blood markers that reflect bone turnover can shift during DMPA use, but interpreting those markers is tricky. Bone turnover markers offer a snapshot of remodeling activity, but they do not reliably predict how much density you will actually gain or lose. Detectable changes in density itself require 12 to 24 months of monitoring to show up on a scan.⁴ This means routine bone-density testing for every DMPA user is not especially informative, though that has not stopped a substantial number of physicians from ordering it anyway.

What Happens When You Stop

This is where the picture brightens considerably. A review of the available evidence found that bone density consistently returned toward or to baseline values after women stopped DMPA, regardless of their age. Recovery was detectable as early as 24 weeks after the last injection and continued for as long as researchers followed participants. Past DMPA users ended up with bone density similar to women who had never used the drug.⁵

A study of women aged 25 to 35 showed that significant increases in bone density occurred through 96 weeks after stopping DMPA, though the hip and spine recovered at slightly different speeds.⁶ Adolescents appear to recover as well. One study tracking teens found that spine density returned to baseline within about 60 weeks of their last injection, while the hip took longer, with full recovery reached at roughly 240 weeks (about four and a half years). By that point, spine density was actually about 4.7 percent above where it had been before DMPA started, reflecting the normal bone gain you would expect in a still-growing skeleton.

The pattern is reassuring overall. The bone loss during DMPA use looks more like a temporary pause in normal bone maintenance than a permanent loss of structural integrity. Whether a few years of lower density during use has any lasting consequences is a separate and more difficult question.

Does the Bone Loss Lead to Fractures

This is the question that actually matters for your health, and the evidence is surprisingly murky. A Cochrane review found no published randomized trial linking DMPA use to fractures later in life. An earlier systematic review also found no clear relationship between DMPA and fracture risk, even though the association with bone density loss was well established. The clinical significance of the density changes, the review noted, was unclear.⁷

Not all data points in the same direction, though. A separate Cochrane review looking specifically at fracture risk found that DMPA use was associated with a higher fracture odds compared to nonuse, with an overall odds ratio of about 1.44. The association was stronger among women over 50, those who used it regularly, and those who used it for more than four years.⁸ Those numbers sound concerning, but there is an important wrinkle.

A large cohort study of over 312,000 women found that DMPA users did fracture more often than nonusers, with a crude fracture rate of about 9.1 per 1,000 person-years versus 7.3 for nonusers. But the study also found that DMPA users already had a higher fracture risk before they ever started the drug, with a rate ratio of 1.28 before use began. After starting DMPA, fracture risk did not meaningfully increase beyond that pre-existing baseline. The researchers concluded that the higher fracture rate among DMPA users may reflect pre-existing characteristics of the women who chose DMPA rather than a direct effect of the drug itself.⁹

This is a classic confounding problem. Women who choose Depo-Provera may differ in many ways from women who choose other methods. They may be more physically active in ways that increase injury risk, or they may have other health or lifestyle factors associated with fracture. Observational studies cannot fully untangle these threads, and running a randomized trial large enough to detect a fracture difference over many years has never been done. So the honest answer is: DMPA clearly lowers bone density temporarily, but whether it actually causes fractures remains unproven.

Teenagers and Young Adults

Adolescence is when you build the majority of your lifetime bone mass. A contraceptive that reduces bone density during this critical window raises understandable concern. Studies do confirm that DMPA decreases bone density in teens, and the effect stands in sharp contrast to what happens on other methods. In one prospective study, bone density decreased 1.5 percent after one year in Depo-Provera users, while it increased 2.9 percent in control subjects who were gaining bone on schedule. After two years, Depo-Provera users had lost a cumulative 3.1 percent, while controls had gained 9.5 percent.¹⁰ That gap is striking, because it represents not just a loss but a missed opportunity for the normal bone accrual that happens during those years.

However, the recovery data for teens is encouraging. As described above, adolescent users who stopped DMPA saw their spine density return to baseline within about a year, and hip density caught up over a longer period. By several years post-discontinuation, their bone measurements looked like those of peers who had never used the method.¹¹ The Society for Adolescent Medicine reviewed the evidence and recommended that clinicians continue to prescribe DMPA to most adolescents who want it, with appropriate counseling about risks and benefits. Their position paper emphasized the low demonstrated fracture risk, the evidence for at least partial recovery, and the need to weigh bone concerns against the real-world consequences of teen pregnancy.¹²

That last point is worth sitting with. Depo-Provera is one of the most effective reversible contraceptives available, and it is particularly useful for people who cannot reliably take a daily pill or who have conditions that make estrogen-containing methods risky. For a teenager choosing between an imperfect contraceptive that protects bone and a highly effective one that temporarily weakens it, the stakes on both sides are real.

The FDA Warning and How It Changed Practice

In 2004, the FDA added a black box warning to Depo-Provera’s label advising that the drug should not be used as a long-term contraceptive (beyond two years) unless other methods were inadequate. The warning was based on the bone density data available at the time. It rattled both patients and providers.

A survey of Florida obstetrician-gynecologists after the warning found that nearly half placed a time limit on DMPA use, and two-thirds said their limit was directly based on the black box warning. About 65 percent were ordering bone density scans solely because a patient was using DMPA, with most citing the warning as the reason.¹³ There was also a trend toward fewer DMPA prescriptions overall, though the shift was not statistically significant in that survey.

Many reproductive health experts have argued that the black box warning overreacted to the evidence. The bone loss is real but largely reversible, no randomized trial has connected DMPA to fractures, and the warning may have discouraged use of an important contraceptive option for people who had few good alternatives. The Society for Adolescent Medicine’s position paper pushed back explicitly, and the American College of Obstetricians and Gynecologists has similarly stated that concerns about bone density should not prevent use of DMPA in most patients. Routine bone density screening for DMPA users is not recommended by most guidelines, since the clinical significance of the changes remains uncertain and the scans rarely change management.

How Depo-Provera Compares to Other Contraceptives

Not all hormonal contraceptives have the same effect on bone. In a three-year study comparing DMPA, low-dose oral contraceptive pills, and nonhormonal methods, DMPA users lost about 3.7 percent of lumbar spine density and 5.2 percent at the femoral neck. Oral contraceptive users lost modest amounts (0.5 percent and 1.3 percent, respectively), while nonhormonal users actually gained small amounts of bone.¹⁴ Another study found that combined oral contraceptive pills were actually associated with increases in bone density, suggesting they may have a modest protective effect.¹⁵

The adolescent study mentioned earlier also compared DMPA to levonorgestrel implants (Norplant) and found that implant users gained bone at rates comparable to controls, while DMPA users lost it.¹⁶ Results for levonorgestrel implants across adult studies have been more mixed, with one review describing them as conflicting.¹⁷ A cross-sectional study of long-term users in Thailand found that bone density in Norplant users and DMPA users was actually similar, suggesting the two progestin-only methods may converge in their effects over many years of use.¹⁸

The levonorgestrel-releasing intrauterine system (hormonal IUD) is a different story. Because it works primarily through local effects in the uterus with much lower systemic hormone levels, it has far less impact on bone. In a head-to-head trial of DMPA versus a hormonal IUD for endometriosis maintenance therapy, the IUD group actually gained bone over three years while the DMPA group lost it.¹⁹ If you are choosing a long-acting method and bone health is a priority, the hormonal IUD is probably the most bone-friendly option in the long-acting category.

Subcutaneous Versus Intramuscular Formulations

Depo-Provera comes in two formulations: the original intramuscular injection (DMPA-IM, 150 mg) and a subcutaneous version (DMPA-SC, 104 mg) that delivers a lower dose. Some people have wondered whether the lower-dose subcutaneous form might be easier on bone. A two-year randomized trial found that bone loss was marginally smaller with the subcutaneous version at both the hip and spine, but by the end of a third year the differences between the two formulations were no longer statistically significant.²⁰ A systematic review confirmed no meaningful difference in bone density changes between the two forms at two years of use.²¹ Both formulations showed recovery of bone density after discontinuation. So while the subcutaneous version has practical advantages (it can be self-administered at home), choosing it specifically for bone protection is not well supported.

When DMPA Is Used for Endometriosis

DMPA is not just a contraceptive. It is also used to manage endometriosis-associated pain, and in that context the bone density question takes on a slightly different shape. Women with endometriosis may need to use DMPA for extended periods, well beyond the two-year mark the FDA warning targets, because the alternative is uncontrolled pain or surgical intervention.

A randomized study comparing subcutaneous DMPA to elagolix (a newer oral medication for endometriosis) found that both treatments produced only minimal bone density changes over 24 weeks, and the changes were similar between groups.²² This shorter-duration finding may not capture what happens with years of use, but it does suggest that DMPA is not uniquely harmful to bone among endometriosis treatments. Many of the drugs used to manage endometriosis suppress estrogen to some degree, so the bone tradeoff is common across the treatment landscape.

For women using DMPA specifically for endometriosis, the three-year comparison with a hormonal IUD is worth noting. That trial showed the IUD performing comparably for symptom control while being much kinder to bone.²³ Clinicians managing endometriosis patients often weigh these options against each other, and bone density is one factor among several that tilt the decision.

Trabecular Bone and What the Scans Miss

Most of the research on DMPA and bone uses dual-energy X-ray absorptiometry scans, which measure bone mineral density as a single number at a given site. But bone is not one uniform substance. Trabecular bone, the spongy interior tissue found especially in the spine and at the ends of long bones, is more metabolically active and more sensitive to hormonal changes than the dense outer cortical bone. You might expect DMPA to hit trabecular bone particularly hard.

Interestingly, one study that specifically examined trabecular bone in long-term DMPA users found no statistically significant difference compared to women who had never used the drug.²⁴ This is a single study with a limited sample, so it should not be over-interpreted. But it adds another layer to the story: the density changes seen on standard scans may not fully reflect what is happening at the structural level. Bone quality involves more than how much mineral is packed into a given area. Microarchitecture, collagen cross-linking, and repair capacity all contribute to whether a bone actually breaks under stress. Standard density scans cannot capture those dimensions, and none of the DMPA studies have been able to measure them at scale.